

- PreF and preF–HN immunogens are stable for over a month at 37 °C, the lyophilized product may be stable at room temperature for months.

- Recombinant vaccine production is scalable, cost-effective vaccine production can be achieved.

Development Stage: Preclinical Research.

Inventors: Barney Graham, Ph.D. (NIAID); Guillaume Stewart-Jones, Ph.D. (NIAID).

Intellectual Property: HHS Reference Number E–153–2019 includes U.S. Provisional Patent Application Number 62/946,902 filed 12/11/2019.

Licensing Contact: To license this technology, please contact Amy F. Petrik, Ph.D., 240–627–3721; amy.petrik@nih.gov.

Dated: April 12, 2020.

Wade W. Green,

Acting Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2020–08561 Filed 4–22–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Thio Compounds and Thalidomide Analogues for the Treatment of Neurological Diseases

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute on Aging and the National Cancer Institute, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and foreign Patents and Patent Applications listed in the Supplementary Information section of this notice to AevisBio, Inc. located in 814 W Diamond Ave., Suite 203, Gaithersburg, MD 20870.

DATES: Only written comments and/or applications for a license which are received by the National Institute on Aging c/o National Cancer Institute's Technology Transfer Center on or before May 8, 2020 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Merissa Baxter, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, 9609

Medical Center Drive, Rm. 1E406 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850–9702, Telephone: 240–276–7234, Email: merissa.baxter@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectually Property

United States Patent No. 8,927,725, issued January 6, 2015 and entitled “Thio Compounds” [HHS Reference No. E–045–2012–0–US–01]; United States Patent No. 9,084,783, issued July 21, 2015 and entitled “Thio Compounds” [HHS Reference No. E–045–2012–0–US–02]; United States Patent No. 9,623,020, issued April 18, 2017 and entitled “Thio Compounds” [HHS Reference No. E–045–2012–0–US–03]; United States Patent No. 10,220,028, issued March 5, 2019 and entitled “Thio Compounds” [HHS Reference No. E–045–2012–0–US–04]; US Provisional Patent Application No. 62/235,105, filed on September 30, 2015 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–US–01]; PCT Patent Application No. PCT/US2016/054430, filed on September 29, 2016 and entitled, “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–PCT–02]; Australian Patent Application No. 2016330967, filed on September 29, 2016 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–AU–03]; Canadian Patent Application No. 3000661, filed on September 29, 2019 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–CA–04]; European Patent Application No. 16782148.7, filed on September 29, 2019 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–EP–05]; South Korean Patent Application No. 10–2018–7012347, filed on April 13, 2018 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–0–KR–06]; and United States Patent Application No. 15/764,193, filed on March 28, 2018 and entitled “Thalidomide Analogs and Methods of Use” [HHS Reference No. E–208–2015–US–07].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be world-wide, and the field of use may be limited to the use of Licensed Patent Rights for the following: “The development, production, and commercialization of a select subset of thalidomide/lenalidomide/pomalidomide (POMA)

analogue compounds for the therapeutic treatment of neurological disorders prevalent in aging: Specifically, Traumatic Brain Injury (TBI), Alzheimer's disease (AD), Parkinson's disease (PD), and Multiple Sclerosis (MS).”

These technologies disclose novel thalidomide, lenalidomide, and pomalidomide analogues that can potentially be used for the treatment of neurological diseases, autoimmunity, and/or cancer.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Institute on Aging receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 13, 2020.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2020–08560 Filed 4–22–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA–2020–0002; Internal Agency Docket No. FEMA–B–2014]

Proposed Flood Hazard Determinations

AGENCY: Federal Emergency Management Agency; DHS.

ACTION: Notice; correction.

SUMMARY: On March 13, 2020, FEMA published in the **Federal Register** a proposed flood hazard determination notice that contained an erroneous

table. This notice provides corrections to that table, to be used in lieu of the information published. The table provided here represents the proposed flood hazard determinations and communities affected for Ellsworth County, Kansas and Incorporated Areas.

DATES: Comments are to be submitted on or before June 11, 2020.

ADDRESSES: The Preliminary Flood Insurance Rate Map (FIRM), and where applicable, the Flood Insurance Study (FIS) report for each community are available for inspection at both the online location and the respective Community Map Repository address listed in the table below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at <https://msc.fema.gov> for comparison.

You may submit comments, identified by Docket No. FEMA-B-2014, to Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646-7659, or (email) patrick.sacbibit@fema.dhs.gov.

FOR FURTHER INFORMATION CONTACT: Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646-7659, or (email) patrick.sacbibit@fema.dhs.gov; or visit the FEMA Mapping and Insurance eXchange (FMIX) online at https://www.floodmaps.fema.gov/fhm/fmx_main.html.

SUPPLEMENTARY INFORMATION: FEMA proposes to make flood hazard determinations for each community listed in the table below, in accordance with Section 110 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4104, and 44 CFR 67.4(a).

These proposed flood hazard determinations, together with the floodplain management criteria required by 44 CFR 60.3, are the minimum that are required. They should not be construed to mean that the community must change any existing ordinances that are more stringent in their floodplain management requirements. The community may at any time enact stricter requirements of its own, or pursuant to policies established by other Federal, State, or regional entities. These flood hazard determinations are used to meet the floodplain management requirements of the NFIP and are also used to calculate the appropriate flood insurance premium rates for new buildings built after the FIRM and FIS report become effective.

Use of a Scientific Resolution Panel (SRP) is available to communities in support of the appeal resolution process. SRPs are independent panels of experts in hydrology, hydraulics, and other pertinent sciences established to review conflicting scientific and technical data and provide recommendations for resolution. Use of the SRP may only be exercised after FEMA and local communities have been engaged in a collaborative consultation process for at least 60 days without a mutually acceptable resolution of an

appeal. Additional information regarding the SRP process can be found online at https://floodsrp.org/pdfs/srp_fact_sheet.pdf.

The communities affected by the flood hazard determinations are provided in the table below. Any request for reconsideration of the revised flood hazard determinations shown on the Preliminary FIRM and FIS report that satisfies the data requirements outlined in 44 CFR 67.6(b) is considered an appeal. Comments unrelated to the flood hazard determinations will also be considered before the FIRM and FIS report are made final.

Correction

In the proposed flood hazard determination notice published at 85 FR 14694 in the March 13, 2020, issue of the **Federal Register**, FEMA published a table titled Ellsworth County, Kansas and Incorporated Areas. This table contained inaccurate information as to the community map repository for the City of Lorraine featured in the table.

In this document, FEMA is publishing a table containing the accurate information. The information provided below should be used in lieu of that previously published. (Catalog of Federal Domestic Assistance No. 97.022, "Flood Insurance.")

Michael M. Grimm,

Assistant Administrator for Risk Management, Department of Homeland Security, Federal Emergency Management Agency.

Community	Community map repository address
Ellsworth County, Kansas and Incorporated Areas Project: 17-07-0009S Preliminary Date: August 14, 2019	
City of Holyrood	City Hall, 110 South Main Street, Holyrood, KS 67450.
City of Lorraine	City Hall, 238 Main Street, Lorraine, KS 67459.
Unincorporated Areas of Ellsworth County	Ellsworth County Courthouse, 210 North Kansas Avenue, Ellsworth, KS 67439.

[FR Doc. 2020-08455 Filed 4-22-20; 8:45 am]

BILLING CODE P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

[FWS-R2-ES-2020-N054;
FXES1113020000-201-FF02ENEH00]

Endangered and Threatened Wildlife and Plants; Recovery Permit Applications

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of receipt of permit applications; request for comments.

SUMMARY: We, the U.S. Fish and Wildlife Service, invite the public to comment on the following applications for a permit to conduct activities intended to recover and enhance endangered species survival. With some exceptions, the Endangered Species Act of 1973, as amended (ESA), prohibits certain activities that may impact endangered species unless a Federal permit allows such activity. The ESA also requires that we invite public comment before issuing these permits.

DATES: To ensure consideration, please submit your written comments by May 26, 2020.

ADDRESSES:

Document availability: Request documents by phone or email: Susan Jacobsen, 505-248-6641, susan_jacobsen@fws.gov.

Comment submission: Submit comments by email to fw2_te_permits@fws.gov. Please specify the permit you are interested in by number (e.g., Permit No. TE-123456).

FOR FURTHER INFORMATION CONTACT: Susan Jacobsen, Chief, Classification